Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183685 | 1.00 | GCK (0.37) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL20649259 | 0.89 | NPC1 (0.39) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL21875664 | 0.88 | CDK2 (0.40) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL30183187 | 0.88 | CDK2 (0.40) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL20649016 | 0.83 | SMN1; SMN2 (0.37) | GCKNPC1RAB9ASMN1; SMN2RET | |
| SCHEMBL30183889 | 0.83 | SMN1; SMN2 (0.37) | GCKNPC1RAB9ASMN1; SMN2RET | |
| SCHEMBL30183920 | 0.81 | CDK2 (0.40) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL20649307 | 0.81 | CDK2 (0.40) | GCKNPC1RAB9AGAAKDM4E | |
| SCHEMBL21875654 | 0.81 | CDK2 (0.38) | RET | |
| SCHEMBL30183630 | 0.81 | CDK2 (0.38) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | GCK 67/4885NPC1 489/4885RAB9A 1097/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | GCK 56/4885NPC1 371/4885RAB9A 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.